Michael Lim

List of Publications by Year
in descending order

328 papers	19,807 citations	22153 59 h-index	13771 129 g-index
332 all docs	332 docs citations	332 times ranked	24583 citing authors

#	Article	IF	Citations
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-Oncology, 2023, 25, 123-134.	1.2	150
2	Internal neurolysis versus intraoperative glycerin rhizotomy for trigeminal neuralgia. Journal of Neurosurgery, 2023, 138, 270-275.	1.6	1
3	Mutation status and postresection survival of patients with nonâ€“small cell lung cancer brain metastasis: implications of biomarker-driven therapy. Journal of Neurosurgery, 2022, 136, 56-66.	1.6	3
4	Impact of international research fellows in neurosurgery: results from a single academic center. Journal of Neurosurgery, 2022, 136, 295-305.	1.6	2
5	Emerging Technologies for Non-invasive Monitoring of Treatment Response to Immunotherapy for Brain Tumors. NeuroMolecular Medicine, 2022, 24, 74-87.	3.4	3
6	Synergy between glutamate modulation and antiâ€“programmed cell death protein 1 immunotherapy for glioblastoma. Journal of Neurosurgery, 2022, 136, 379-388.	1.6	11
7	The safety and efficacy of dexamethasone in the perioperative management of glioma patients. Journal of Neurosurgery, 2022, 136, 1062-1069.	1.6	7
8	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	7.0	18
9	Is There a Role for Immunotherapy in Central Nervous System Cancers?. Hematology/Oncology Clinics of North America, 2022, 36, 237-252.	2.2	5
10	Quantitative Bioluminescence Tomography for In Vivo Volumetric-Guided Radiotherapy. Methods in Molecular Biology, 2022, 2393, 701-731.	0.9	3
11	Introduction. Immunology of neurosurgical diseases. Neurosurgical Focus, 2022, 52, E1.	2.3	0
12	Advances in Immunotherapies for Gliomas. Current Neurology and Neuroscience Reports, 2022, 22, 1-10.	4.2	9
13	Clinical features and surgical outcomes of intracranial and spinal cord subependymomas. Journal of Neurosurgery, 2022, 137, 931-942.	1.6	3
14	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology Advances, 2022, 4, vdac025.	0.7	18
15	CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future. Frontiers in Immunology, 2022, 13, 817296.	4.8	35
16	Quality of Life and Role of Palliative and Supportive Care for Patients With Brain Metastases and Caregivers: A Review. Frontiers in Neurology, 2022, 13, 806344.	2.4	4
17	Case Series in the Utility of Invasive Blood Pressure Monitoring in Microvascular Decompression. Operative Neurosurgery, 2022, 22, 262-268.	0.8	1
18	The Molecular Basis and Pathophysiology of Trigeminal Neuralgia. International Journal of Molecular Sciences, 2022, 23, 3604.	4.1	20

#	Article	IF	Citations
19	The roles of thermal and mechanical stress in focused ultrasound-mediated immunomodulation and immunotherapy for central nervous system tumors. Journal of Neuro-Oncology, 2022, 157, 221-236.	2.9	5
20	Cranioplasty With Customized Craniofacial Implants and Intraoperative Resizing for Single-Stage Reconstruction Following Oncologic Resection of Skull Neoplasms. Journal of Craniofacial Surgery, 2022, 33, 1641-1647.	0.7	0
21	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28, 2567-2578.	7.0	20
22	Applying Synthetic Biology with Rational Design to Natureâ€™s Greatest Challenges: Bioengineering Immunotherapeutics for the Treatment of Glioblastoma. Immuno, 2022, 2, 40-51.	1.5	0
23	ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. Neuro-Oncology, 2022, 24, 888-900.	1.2	20
24	Calcium-Related Gene Signatures May Predict Prognosis and Level of Immunosuppression in Gliomas. Frontiers in Oncology, 2022, 12, .	2.8	2
25	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncology, 2022, 24, 1935-1949.	1.2	165
26	The Role of Myeloid Cells in GBM Immunosuppression. Frontiers in Immunology, 2022, 13, .	4.8	12
27	The future of cancer immunotherapy for brain tumors: a collaborative workshop. Journal of Translational Medicine, 2022, 20, .	4.4	7
28	Learning-based analysis of amide proton transfer-weighted MRI to identify true progression in glioma patients. NeuroImage: Clinical, 2022, , 103121.	2.7	4
29	A review of glioblastoma immunotherapy. Journal of Neuro-Oncology, 2021, 151, 41-53.	2.9	159
30	Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials, 2021, 266, 120431.	11.4	131
31	Approach to the meningioma patient. , 2021, , 118-135.		0
32	OUP accepted manuscript. Neuro-Oncology, 2021, , .	1.2	0
33	Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. Journal of Neuro-Oncology, 2021, 152, 125-134.	2.9	7
34	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. Neuro-Oncology, 2021, 23, 506-507.	1.2	0
35	In Reply: Absence of Ischemic Injury After Sacrificing the Superior Petrosal Vein During Microvascular Decompression. Operative Neurosurgery, 2021, 20, E260-E260.	0.8	1
36	Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma. OncoImmunology, 2021, 10, 1940673.	4.6	7

#	Article	IF	Citations
37	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neuro-Oncology Advances, 2021, 3, vdab035.	0.7	3
38	Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma. OncoImmunology, 2021, 10, 1956142.	4.6	22
39	Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells. Cancer Research, 2021, 81, 2457-2469.	0.9	31
40	Combination immunotherapy strategies for glioblastoma. Journal of Neuro-Oncology, 2021, 151, 375-391.	2.9	38
41	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2074-TPS2074.	1.6	2
42	Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence. Cancers, 2021, 13, 2408.	3.7	24
43	Bone Cement Internal Auditory Canal Reconstruction to Reduce CSF Leak After Vestibular Schwannoma Retrosigmoid Approach. Otology and Neurotology, 2021, 42, e1101-e1105.	1.3	3
44	Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma. Science Translational Medicine, 2021, 13, .	12.4	8
45	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
46	A Crowdsourced Consensus on Supratotal Resection Versus Gross Total Resection for Anatomically Distinct Primary Glioblastoma. Neurosurgery, 2021, 89, 712-719.	1.1	19
47	Roles of Neutrophils in Glioma and Brain Metastases. Frontiers in Immunology, 2021, 12, 701383.	4.8	41
48	RADI-23. Exploring the optimal timing of routine initial surveillance MRI following treatment of brain metastases with stereotactic radiosurgery: a comparison of two approaches. Neuro-Oncology Advances, 2021, 3, iii23-iii23.	0.7	0
49	Quantitative Bioluminescence Tomography-Guided Conformal Irradiation for Preclinical Radiation Research. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1310-1321.	0.8	11
50	The Challenges and Future of Immunotherapy for Gliomas. Cancer Journal (Sudbury, Mass), 2021, 27, 371-378.	2.0	3
51	Development of new brain metastases in triple negative breast cancer. Journal of Neuro-Oncology, 2021, 152, 333-338.	2.9	8
52	Unique challenges for glioblastoma immunotherapyâ€"discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59
53	PD-1+ Monocytes Mediate Cerebral Vasospasm Following Subarachnoid Hemorrhage. Neurosurgery, 2021, 88, 855-863.	1.1	11
54	In Vivo Evaluation of Near-Infrared Fluorescent Probe for TIM3 Targeting in Mouse Glioma. Molecular Imaging and Biology, 2021, , 1.	2.6	2

#	Article	IF	Citations
55	CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548. Neuro-Oncology, 2021, 23, vi55-vi56.	1.2	16
56	Absence of Ischemic Injury after Sacrificing the Superior Petrosal Vein during Microvascular Decompression. Operative Neurosurgery, 2020, 18, 316-320.	0.8	12
57	Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy. Advances in Radiation Oncology, 2020, 5, 62-69.	1.2	9
58	CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma. Cancer Gene Therapy, 2020, 27, 669-679.	4.6	15
59	A Phase 2 Study of Post-Operative Stereotactic Body Radiation Therapy (SBRT) for Solid Tumor Spine Metastases. International Journal of Radiation Oncology Biology Physics, 2020, 106, 261-268.	0.8	49
60	Chronic Lymphocytic Leukemia Resulting in Hemorrhagic Brain Masses After Sepsis. Neurohospitalist, The, 2020, 10, 64-68.	0.8	1
61	Integrin Î±6 signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells. Oncogene, 2020, 39, 2156-2169.	5.9	23
62	PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. Journal of Neuropathology and Experimental Neurology, 2020, 79, 74-85.	1.7	10
63	InÂVivo Bioluminescence Tomography Center of Mass-Guided Conformal Irradiation. International Journal of Radiation Oncology Biology Physics, 2020, 106, 612-620.	0.8	17
64	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
65	The Effects of Postoperative Neurological Deficits on Survival in Patients With Single Brain Metastasis. Operative Neurosurgery, 2020, 19, 628-634.	0.8	8
66	Scalp Invasion by Atypical or Anaplastic Meningioma Is a Risk Factor for Development of Systemic Metastasis. World Neurosurgery, 2020, 142, e133-e139.	1.3	8
67	Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biology, 2020, 21, 216.	8.8	73
68	Alternative Checkpoints as Targets for Immunotherapy. Current Oncology Reports, 2020, 22, 126.	4.0	12
69	Cottonoid Sliders: A Simple and Cost-Effective Tool for Retractorless Intracranial Surgery. Operative Neurosurgery, 2020, 19, E428-E431.	0.8	3
70	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. JAMA Oncology, 2020, 6, 1003.	7.1	805
71	Adult immuno-oncology: using past failures to inform the future. Neuro-Oncology, 2020, 22, 1249-1261.	1.2	19
72	ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics, 2020, 10, 5943-5956.	10.0	76

#	Article	IF	Citations
73	Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma. Case Reports in Oncology, 2020, 13, 508-514.	0.7	15
74	A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. Journal of Neuro-Oncology, 2020, 148, 419-431.	2.9	48
75	New Prospects for Molecular Targets for Chordomas. Neurosurgery Clinics of North America, 2020, 31, 289-300.	1.7	9
76	A Dose-Response Model of Local Tumor Control Probability After Stereotactic Radiosurgery for Brain Metastases Resection Cavities. Advances in Radiation Oncology, 2020, 5, 840-849.	1.2	4
77	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. Neuro-Oncology Advances, 2020, 2, vdaa011.	0.7	22
78	Understanding innate immune response in glioblastoma in search of a way forward. Neuro-Oncology, 2020, 22, 444-445.	1.2	1
79	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
80	Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM.. Journal of Clinical Oncology, 2020, 38, 2512-2512.	1.6	9
81	GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2020, 38, TPS2579-TPS2579.	1.6	5
82	Efficacy of osimertinib against EGFRvIII+ glioblastoma. Oncotarget, 2020, 11, 2074-2082.	1.8	37
83	Glycerol Rhizotomy for the Management of Tumor-Associated Trigeminal Neuralgia. Journal of Neurological Surgery, Part B: Skull Base, 2020, 81, .	0.8	0
84	Abstract 4491: Characterizing long non-coding RNA expression of tumor-infiltrating lymphocytes across solid cancers. , 2020, , .		0
85	Immunotherapy and Radiosurgery. , 2020, , 423-436.		0
86	Anticoagulation for Cerebral Venous Sinus Thrombosis after Posterior Fossa Schwannoma Surgery: Worth the Risk?. , 2020, 81, .		0
87	Retrosigmoid approach for glycerin rhizotomy in the treatment of trigeminal neuralgia without overt arterial compression: updated case series. Journal of Neurosurgery, 2020, 132, 1227-1233.	1.6	4
88	NCOG-32. THE SAFETY AND EFFICACY OF DEXAMETHASONE IN THE MANAGEMENT OF GLIOMA PATIENTS. Neuro-Oncology, 2020, 22, ii136-ii136.	1.2	1
89	RTID-11. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii195-ii196.	1.2	0
90	IMMU-13. EFFICACY OF CXCR6 BLOCKADE AS A POTENTIATOR OF ANTI-PD-1 THERAPY FOR THE TREATMENT OF GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii107-ii107.	1.2	1

#	Article	IF	Citations
91	SURG-21. A CROWDSOURCED CONSENSUS ON SUPRATOTAL RESECTION VERSUS GROSS TOTAL RESECTION FOR ANATOMICALLY DISTINCT PRIMARY GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii207-ii208.	1.2	0
92	NCOG-25. EFFICACY OF ANTICONVULSANT THERAPY IN GLIOMA PATIENTS. Neuro-Oncology, 2020, 22, ii134-ii134.	1.2	0
93	IMMU-27. SINGLE CELL RNA-SEQUENCING IDENTIFIES NOVEL BONE MARROW DERIVED MYELOID CELLS IN GLIOBLASTOMA ASSOCIATED WITH TUMOR AGGRESSION. Neuro-Oncology, 2020, 22, ii110-ii110.	1.2	0
94	COVD-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT. Neuro-Oncology, 2020, 22, ii27-ii27.	1.2	0
95	NCOG-05. MANAGEMENT OF BRAIN METASTASIS IN TRIPLE NEGATIVE BREAST CANCER. Neuro-Oncology, 2020, 22, ii130-ii130.	1.2	0
96	Commentary: Does Stereotactic Radiosurgery Have a Role in the Management of Patients Presenting With 4 or More Brain Metastases?. Neurosurgery, 2019, 84, 567-568.	1.1	0
97	Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors. Frontiers in Immunology, 2019, 10, 1715.	4.8	38
98	Genomeâ€wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types. International Journal of Cancer, 2019, 145, 3425-3435.	5.1	16
99	Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nature Immunology, 2019, 20, 1100-1109.	14.5	421
100	Thalamic gliomas: Advances in the surgical management. , 2019, , 117-135.		0
101	Assessing the Effectiveness of Systemic Therapy after Stereotactic Radiosurgery on Cancer Recurrence and All-Cause Mortality. World Neurosurgery, 2019, 129, e572-e581.	1.3	0
102	Deferred Radiotherapy After Debulking of Non-functioning Pituitary Macroadenomas: Clinical Outcomes. Frontiers in Oncology, 2019, 8, 660.	2.8	4
103	Association Between Radiofrequency Rhizotomy Parameters and Duration of Pain Relief in Trigeminal Neuralgia Patients with Recurrent Pain. World Neurosurgery, 2019, 129, e128-e133.	1.3	7
104	Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated With Reduced Efficacy of Radiotherapy. Neurosurgery, 2019, 85, 441-453.	1.1	33
105	Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced somatic mutation rates in survival outliers of glioblastoma. Acta Neuropathologica Communications, 2019, 7, 88.	5.2	8
106	Utilization of the Nasoseptal Flap for Repair of Cerebrospinal Fluid Leak after Endoscopic Endonasal Approach for Resection of Pituitary Tumors. Brain Tumor Research and Treatment, 2019, 7, 10.	1.0	11
107	Surgical Resection for Primary Central Nervous System Lymphoma: A Systematic Review. World Neurosurgery, 2019, 126, e1436-e1448.	1.3	23
108	A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials. Cancers, 2019, 11, 537.	3.7	66

#	Article	IF	Citations
109	Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. Journal of Neuro-Oncology, 2019, 143, 241-249.	2.9	88
110	Bespoke immunotherapy: how close are we?. Neuro-Oncology, 2019, 21, 289-290.	1.2	0
111	Risk of Developing Postoperative Deficits Based on Tumor Location after Surgical Resection of an Intracranial Meningioma. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, 059-066.	0.8	13
112	TMIC-14. PD-L1 EXPRESSION IS NEGATIVELY CORRELATED TO OUTCOMES IN PATIENTS WITH MGMT METHYLATED PROMOTERS IN GBM. Neuro-Oncology, 2019, 21, vi250-vi250.	1.2	0
113	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. Neuro-Oncology, 2019, 21, vi12-vi12.	1.2	3
114	IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2019, 21, vi122-vi123.	1.2	1
115	SURG-16. SUPRATOTAL VERSUS GROSS TOTAL RESECTION OF GLIOBLASTOMA: A SYSTEMATIC REVIEW. Neuro-Oncology, 2019, 21, vi243-vi243.	1.2	0
116	Carboxylated branched poly(Î²-amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing. Science Advances, 2019, 5, eaay3255.	10.3	127
117	Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. Clinical Cancer Research, 2019, 25, 552-561.	7.0	104
118	Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33. Translational Oncology, 2019, 12, 96-105.	3.7	31
119	Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.. Journal of Clinical Oncology, 2019, 37, 2017-2017.	1.6	10
120	Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).. Journal of Clinical Oncology, 2019, 37, 2032-2032.	1.6	33
121	Why is immunotherapy for glioblastoma â€œLagâ€•ging. Oncotarget, 2019, 10, 1228-1229.	1.8	2
122	Updated risk models demonstrate low risk of symptomatic radionecrosis following stereotactic radiosurgery for brain metastases. , 2019, 10, 32.		15
123	PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors. Cureus, 2019, 11, e6352.	0.5	7
124	Abstract B165: Investigating in vivo synergistic effect of checkpoint blockade and radiation therapy against chordomas in a humanized mouse model. , 2019, , .		1
125	Extracranial Abscopal Responses after Radiation Therapy for Intracranial Metastases: A Review of the Clinical Literature and Commentary on Mechanism. Cureus, 2019, 11, e4207.	0.5	7
126	Adult Cranioplasty Reconstruction With Customized Cranial Implants: Preferred Technique, Timing, and Biomaterials. Journal of Craniofacial Surgery, 2018, 29, 887-894.	0.7	64

#	Article	IF	Citations
127	Immunotherapy for Glioblastoma: Playing Chess, Not Checkers. Clinical Cancer Research, 2018, 24, 4059-4061.	7.0	14
128	Current state of immunotherapy for glioblastoma. Nature Reviews Clinical Oncology, 2018, 15, 422-442.	27.6	873
129	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 916-925.	0.8	257
130	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology, 2018, 20, 674-686.	1.2	364
131	The Relevance of Simpson Grade Resections in Modern Neurosurgical Treatment of World Health Organization Grade I, II, and III Meningiomas. World Neurosurgery, 2018, 109, e588-e593.	1.3	37
132	TMOD-37. IN VIVO SYNERGISTIC EFFECT OF CHECKPOINT BLOCKADE AND RADIATION THERAPY AGAINST CHORDOMAS IN A HUMANIZED MOUSE MODEL. Neuro-Oncology, 2018, 20, vi276-vi276.	1.2	1
133	ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 582 Td (Neuro-Oncology, 2018, 20, vi10-vi10.	1.2	6
134	ATIM-21. UPDATED RESULTS OF A PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2018, 20, vi5-vi5.	1.2	0
135	RTHP-13. TUMOR-TREATING FIELDS THERAPY IS COMPATIBLE WITH STANDARD CHEMORADIOTHERAPY FOR GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi228-vi228.	1.2	0
136	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. OncoImmunology, 2018, 7, e1500108.	4.6	52
137	EXTH-03. LOCAL ONCOLYTIC ADENOVIRUS TREATMENT AFFECTS BOTH THE INNATE AND ADAPTIVE ARMS OF THE IMMUNE SYSTEM AND PROVIDES AN AVENUE FOR ENHANCING IMMUNOTHERAPIES FOR GBM. Neuro-Oncology, 2018, 20, vi85-vi85.	1.2	0
138	Vessel Wall MRI for Targeting Biopsies of Intracranial Vasculitis. American Journal of Neuroradiology, 2018, 39, 2034-2036.	2.4	48
139	Expression of LAGâ€3 and efficacy of combination treatment with antiâ€LAGâ€3 and antiâ€PDâ€1 monoclonal antibodies in glioblastoma. International Journal of Cancer, 2018, 143, 3201-3208.	5.1	101
140	Distinguishing True Progression From Radionecrosis After Stereotactic Radiation Therapy for Brain Metastases With Machine Learning and Radiomics. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1236-1243.	0.8	103
141	Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nature Biomedical Engineering, 2018, 2, 850-864.	22.5	214
142	Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8583-E8584.	7.1	5
143	TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology, 2018, 7, e1466769.	4.6	217
144	In Reply to Yilmaz etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 101, 998-999.	0.8	1

#	Article	IF	Citations
145	Immediate and Long-Term Outcomes of Microvascular Decompression for Mixed Trigeminal Neuralgia. World Neurosurgery, 2018, 117, e300-e307.	1.3	18
146	Absence of host NF-Î²B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunology, Immunotherapy, 2018, 67, 1491-1503.	4.2	26
147	Local recurrence patterns after postoperative stereotactic radiation surgery to resected brain metastases: A quantitative analysis to guide target delineation. Practical Radiation Oncology, 2018, 8, 388-396.	2.1	14
148	Contrast-Enhanced CISS Imaging for Evaluation of Neurovascular Compression in Trigeminal Neuralgia: Improved Correlation with Symptoms and Prediction of Surgical Outcomes. American Journal of Neuroradiology, 2018, 39, 1724-1732.	2.4	23
149	Risk of Developing Postoperative Deficits Based on Tumor Location after Surgical Resection of an Intracranial Meningioma. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, S1-S188.	0.8	1
150	Abstract 1736: The combination of CXCR4 and checkpoint receptor inhibition improves survival in an orthotopic murine glioma model. , 2018, , .		3
151	PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget, 2018, 9, 19177-19191.	1.8	45
152	Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. Oncotarget, 2018, 9, 20681-20697.	1.8	63
153	It takes two: potential therapies and insights involving microglia and macrophages in glioblastoma. Neuroimmunology and Neuroinflammation, 2018, 5, 42.	1.4	19
154	Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells. , 2018, 9, 146.		7
155	Outcomes of Metastatic Brain Lesions Treated with Radioactive Cs-131 Seeds after Surgery: Experience from One Institution. Cureus, 2018, 10, e3075.	0.5	8
156	History of Trigeminal Neuralgia. Advances in Medical Diagnosis, Treatment, and Care, 2018, , 1-31.	0.1	0
157	The Relevance of Simpson Grade Resections in the Modern Neurosurgical Treatment of World Health Organization Grades 1, 2, and 3 Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, S1-S188.	0.8	0
158	Abstract 5874: Targeting DDX3 in medulloblastoma by RK-33. , 2018, , .		0
159	Fire in the Smoke: Battling Brain Tumors. Cerebrum: the Dana Forum on Brain Science, 2018, 2018, .	0.1	0
160	BRAFâ€V600 mutational status affects recurrence patterns of melanoma brain metastasis. International Journal of Cancer, 2017, 140, 2716-2727.	5.1	24
161	Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clinical Cancer Research, 2017, 23, 124-136.	7.0	345
162	Progressive Low-Grade Glioma: Assessment of Prognostic Importance of Histologic Reassessment and MRI Findings. World Neurosurgery, 2017, 99, 751-757.	1.3	19

#	Article	IF	Citations
163	Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature. World Neurosurgery, 2017, 101, 47-56.	1.3	69
164	Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 939-947.	0.8	32
165	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. Clinical Cancer Research, 2017, 23, 3575-3584.	7.0	78
166	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. Neurotherapeutics, 2017, 14, 1049-1065.	4.4	20
167	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Gliomaâ€“Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. Current Neurology and Neuroscience Reports, 2017, 17, 50.	4.2	10
168	Risk Factors for Preoperative Seizures and Loss of Seizure Control in Patients Undergoing Surgery for Metastatic Brain Tumors. World Neurosurgery, 2017, 104, 120-128.	1.3	37
169	Immunotherapy and radiation in glioblastoma. Journal of Neuro-Oncology, 2017, 134, 531-539.	2.9	29
170	Biomarkers and Immunotherapeutic Targets in Glioblastoma. World Neurosurgery, 2017, 102, 494-506.	1.3	29
171	Postoperative sinonasal morbidity in sellar reconstruction: mucosal autograft versus acellular dermal allograft. International Forum of Allergy and Rhinology, 2017, 7, 1178-1185.	2.8	4
172	Targeting cytokines for treatment of neuropathic pain. Scandinavian Journal of Pain, 2017, 17, 287-293.	1.3	118
173	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, The, 2017, 18, 1373-1385.	10.7	776
174	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. Current Treatment Options in Oncology, 2017, 18, 51.	3.0	69
175	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e709-e710.	10.7	5
176	Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10981-E10990.	7.1	217
177	Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas. European Journal of Cancer, 2017, 83, 9-18.	2.8	82
178	Long-term Outcomes With Planned Multistage Reduced Dose Repeat Stereotactic Radiosurgery for Treatment of Inoperable High-Grade Arteriovenous Malformations: An Observational Retrospective Cohort Study. Neurosurgery, 2017, 81, 136-146.	1.1	9
179	Efficacy of primary microvascular decompression versus subsequent microvascular decompression for trigeminal neuralgia. Journal of Neurosurgery, 2017, 126, 1691-1697.	1.6	24
180	Spontaneous Intracranial Hypotension after Vestibular Schwannoma Resection Due to an Unexpected Pathology: Tarlov Cysts. Cureus, 2017, 9, e1261.	0.5	3

#	Article	IF	Citations
181	Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy. Frontiers in Oncology, 2017, 7, 200.	2.8	21
182	Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab Â± ipilimumab: CheckMate 143.. Journal of Clinical Oncology, 2017, 35, 2001-2001.	1.6	2
183	Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.. Journal of Clinical Oncology, 2017, 35, 2042-2042.	1.6	44
184	Neurosurgery concepts: Key perspectives on imaging characteristics of spinal metastases, surgery for low back pain, anesthesia for disc surgery, and laminectomy versus laminectomy and fusion for lumbar spondylolisthesis. , 2017, 8, 9.		1
185	Neurosurgery concepts: Key perspectives on endoscopic versus microscopic resection for pituitary adenomas, surgical decision-making in tuberculum sellae meningiomas, optic nerve mobilization during resection of craniopharyngiomas, and evaluation of headache and quality of life after endoscopic transphenoidal surgery for pituitary adenomas. , 2017, 8, 52.		2
186	Immunotherapy for Glioblastoma. Journal of Clinical & Cellular Immunology, 2016, 7, .	1.5	0
187	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e132-e139.	3.8	13
188	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. Journal of Immunology Research, 2016, 2016, 1-14.	2.2	36
189	Timely stereotactic body radiotherapy (SBRT) for spine metastases using a rapidly deployable automated planning algorithm. SpringerPlus, 2016, 5, 1337.	1.2	2
190	Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines. PLoS ONE, 2016, 11, e0150271.	2.5	21
191	IMST-58. MODULATING THE MYELOID COMPARTMENT TO POTENTIATE ANTI-PD1 MEDIATED IMMUNOTHERAPY AGAINST GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi99-vi99.	1.2	0
192	Antiâ€“PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Science Translational Medicine, 2016, 8, 370ra180.	12.4	243
193	ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi17-vi18.	1.2	43
194	The strategy of repeat stereotactic radiosurgery without whole brain radiation treatment for new brain metastases: Outcomes and implications for follow-up monitoring. Practical Radiation Oncology, 2016, 6, 409-416.	2.1	24
195	High-Resolution MRI Findings following Trigeminal Rhizotomy. American Journal of Neuroradiology, 2016, 37, 1920-1924.	2.4	6
196	Influence of insurance status on survival of adults with glioblastoma multiforme: A populationâ€based study. Cancer, 2016, 122, 3157-3165.	4.1	52
197	Preface. Neurosurgery Clinics of North America, 2016, 27, ix.	1.7	0
198	Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. International Journal of Cancer, 2016, 138, 187-194.	5.1	83

#	Article	IF	Citations
199	Controversies in the Therapy of Brain Metastases: Shifting Paradigms in an Era of Effective Systemic Therapy and Longer-Term Survivorship. Current Treatment Options in Oncology, 2016, 17, 46.	3.0	22
200	Layered Sellar Reconstruction with Avascular Free Grafts: Acceptable Alternative to the Nasoseptal Flap for repair of Low-Volume Intraoperative Cerebrospinal Fluid Leak. American Journal of Rhinology and Allergy, 2016, 30, 367-371.	2.0	25
201	Discussion on. Journal of Craniofacial Surgery, 2016, 27, 1568-1570.	0.7	3
202	Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e251.	6.0	142
203	Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. , 2016, 4, 28.		52
204	Nontyphoidal Salmonellosis, Human Immunodeficiency Virus Infection, and Ischemic Stroke. Open Forum Infectious Diseases, 2016, 3, ofw104.	0.9	0
205	Ganetespib radiosensitization for liver cancer therapy. Cancer Biology and Therapy, 2016, 17, 457-466.	3.4	12
206	A Systematic Analysis of the Reliability of Diffusion Tensor Imaging Tractography for Facial Nerve Imaging in Patients with Vestibular Schwannoma. Journal of Neurological Surgery, Part B: Skull Base, 2016, 77, 314-318.	0.8	17
207	Laser speckle imaging to improve clinical outcomes for patients with trigeminal neuralgia undergoing radiofrequency thermocoagulation. Journal of Neurosurgery, 2016, 124, 422-428.	1.6	7
208	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clinical Cancer Research, 2016, 22, 1161-1172.	7.0	57
209	Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.. Journal of Clinical Oncology, 2016, 34, 2014-2014.	1.6	24
210	A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.. Journal of Clinical Oncology, 2016, 34, TPS2079-TPS2079.	1.6	41
211	Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2016, 34, TPS2080-TPS2080.	1.6	4
212	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e132-e139.	3.8	11
213	Issues to Consider in Designing Immunotherapy Clinical Trials for Glioblastoma Management. Journal of Cancer Therapy, 2016, 07, 573-585.	0.4	1
214	Abstract A046: Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM). , 2016, , .		0
215	IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143. Neuro-Oncology, 2015, 17, v107.3-v107.	1.2	6
216	NIMG-16PSEUDOPROGRESSION AND IMMUNOTHERAPY IN GLIOBLASTOMA: A CASE SERIES FROM COHORT 1 OF CHECKMATE-143 (NCT02017717). Neuro-Oncology, 2015, 17, v156.3-v156.	1.2	0

#	Article	IF	Citations
217	Immediate Single-Stage Cranioplasty Following Calvarial Resection for Benign and Malignant Skull Neoplasms Using Customized Craniofacial Implants. Journal of Craniofacial Surgery, 2015, 26, 1456-1462.	0.7	42
218	Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. Frontiers in Oncology, 2015, 5, 153.	2.8	129
219	Metastatic Extrapulmonary Small Cell Carcinoma to the Cerebellopontine Angle: A Case Report and Review of the Literature. Case Reports in Oncological Medicine, 2015, 2015, 1-6.	0.3	2
220	Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.3	4
221	Neurosurgery concepts: Key perspectives on dendritic cell vaccines, metastatic tumor treatment, and radiosurgery. , 2015, 6, 6.		1
222	NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143. Neuro-Oncology, 2015, 17, v156.4-v157.	1.2	0
223	NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143). Neuro-Oncology, 2015, 17, v157.1-v157.	1.2	0
224	Pituitary adenomas: historical perspective, surgical management and future directions. CNS Oncology, 2015, 4, 411-429.	3.0	73
225	Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation. Neurological Research, 2015, 37, 717-726.	1.3	28
226	Technical note: Orbitozygomatic craniotomy using an ultrasonic osteotome for precise osteotomies. Clinical Neurology and Neurosurgery, 2015, 134, 24-27.	1.4	10
227	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9704-9709.	7.1	317
228	The role of checkpoints in the treatment of GBM. Journal of Neuro-Oncology, 2015, 123, 413-423.	2.9	15
229	Combining immunotherapy with radiation for the treatment of glioblastoma. Journal of Neuro-Oncology, 2015, 123, 459-464.	2.9	14
230	Introduction: brain tumor immunotherapy. Journal of Neuro-Oncology, 2015, 123, 321-322.	2.9	1
231	Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncology, The, 2015, 16, e498-e509.	10.7	660
232	Immunotherapy for glioblastoma: are we finally getting closer?. Neuro-Oncology, 2015, 17, 771-772.	1.2	1
233	Immunomodulation: checkpoint blockade etc.: Fig. 1.. Neuro-Oncology, 2015, 17, vii26-vii31.	1.2	26
234	Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews Neurology, 2015, 11, 504-514.	10.1	307

#	Article	IF	Citations
235	Prognostic factors associated with pain palliation after spine stereotactic body radiation therapy. Journal of Neurosurgery: Spine, 2015, 23, 620-629.	1.7	26
236	Reduced CSF leak in complete calvarial reconstructions of microvascular decompression craniectomies using calcium phosphate cement. Journal of Neurosurgery, 2015, 123, 1476-1479.	1.6	34
237	Neurocytoma of the Spinal Cord. Neurosurgery Clinics of North America, 2015, 26, 109-115.	1.7	5
238	PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. Journal of Neuro-Oncology, 2015, 121, 251-259.	2.9	56
239	Newly diagnosed glioblastoma patients treated with an autologous heat shock protein peptide vaccine: PD-L1 expression and response to therapy.. Journal of Clinical Oncology, 2015, 33, 2011-2011.	1.6	8
240	Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.. Journal of Clinical Oncology, 2015, 33, 3010-3010.	1.6	52
241	Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2015, 33, TPS2077-TPS2077.	1.6	2
242	Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival. Cureus, 2015, 7, e409.	0.5	6
243	Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology, 2015, 29, 331-40.	0.5	45
244	Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model. PLoS ONE, 2014, 9, e101764.	2.5	206
245	The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy. Cancers, 2014, 6, 1953-1985.	3.7	62
246	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
247	STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications. Cancers, 2014, 6, 376-395.	3.7	97
248	Current Vaccine Trials in Glioblastoma: A Review. Journal of Immunology Research, 2014, 2014, 1-10.	2.2	65
249	Factors associated with survival and recurrence for patients undergoing surgery of cerebellar metastases. Neurological Research, 2014, 36, 13-25.	1.3	25
250	Management of Cerebral Brain Metastasis. Current Surgery Reports, 2014, 2, 1.	0.9	0
251	Multidisciplinary Approach for Improved Outcomes in Secondary Cranial Reconstruction. Operative Neurosurgery, 2014, 10, 179-190.	0.8	38
252	Î±5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathologica, 2014, 127, 593-603.	7.7	39

#	Article	IF	Citations
253	Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurgical Review, 2014, 37, 279-286.	2.4	74
254	Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-Oncology, 2014, 16, 113-122.	1.2	400
255	Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?. Future Oncology, 2014, 10, 1277-1297.	2.4	143
256	Immunotherapy for Brain Cancer: Recent Progress and Future Promise. Clinical Cancer Research, 2014, 20, 3651-3659.	7.0	92
257	Planning Evaluation of C-Arm Cone Beam CT Angiography for Target Delineation in Stereotactic Radiation Surgery of Brain Arteriovenous Malformations. International Journal of Radiation Oncology Biology Physics, 2014, 90, 430-437.	0.8	15
258	TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting. Cancer Research, 2014, 74, 5218-5228.	0.9	60
259	Selective cerebral hypothermia induced via hypothermic retrograde jugular vein saline flush in a porcine model. Neurological Research, 2014, 36, 897-902.	1.3	5
260	The role of regulatory T-cells in glioma immunology. Clinical Neurology and Neurosurgery, 2014, 119, 125-132.	1.4	76
261	Identifying Better Surgical Candidates Among Recursive Partitioning Analysis Class 2 Patients who Underwent Surgery for Intracranial Metastases. World Neurosurgery, 2014, 82, e267-e275.	1.3	7
262	The utility of MR enhancement as a noninvasive predictor for high-grade histology in patients with progressive low-grade gliomas: Is histology needed to guide therapy?. Journal of Clinical Oncology, 2014, 32, 2098-2098.	1.6	0
263	Postoperative Anticoagulation in Patients with Mechanical Heart Valves Following Surgical Treatment of Subdural Hematomas. Neurocritical Care, 2013, 19, 90-94.	2.4	16
264	Metastatic Melanoma to the Brain: Surgery and Radiation Is Still the Standard of Care. Current Treatment Options in Oncology, 2013, 14, 264-279.	3.0	19
265	Seizure Control for Patients Undergoing Meningioma Surgery. World Neurosurgery, 2013, 79, 515-524.	1.3	69
266	The Transconjunctival Transorbital Approach: A Keyhole Approach to the Midline Anterior Skull Base. World Neurosurgery, 2013, 80, 864-871.	1.3	35
267	Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas. International Journal of Radiation Oncology Biology Physics, 2013, 86, 343-349.	0.8	757
268	Factors associated with survival for patients with glioblastoma with poor pre-operative functional status. Journal of Clinical Neuroscience, 2013, 20, 818-823.	1.5	33
269	Glycerol rhizotomy via a retrosigmoid approach as an alternative treatment for trigeminal neuralgia. Clinical Neurology and Neurosurgery, 2013, 115, 2454-2456.	1.4	10
270	Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma. Journal of Clinical Neuroscience, 2013, 20, 1422-1426.	1.5	38

#	Article	IF	Citations
271	Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy, 2013, 5, 155-167.	2.0	33
272	Increased Subventricular Zone Radiation Dose Correlates With Survival in Glioblastoma Patients After Gross Total Resection. International Journal of Radiation Oncology Biology Physics, 2013, 86, 616-622.	0.8	121
273	Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. Neurological Research, 2013, 35, 206-211.	1.3	70
274	Multiple resections for patients with glioblastoma: prolonging survival. Journal of Neurosurgery, 2013, 118, 812-820.	1.6	166
275	Glycerol rhizotomy and radiofrequency thermocoagulation for trigeminal neuralgia in multiple sclerosis. Journal of Neurosurgery, 2013, 118, 329-336.	1.6	43
276	A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain. Case Reports in Oncological Medicine, 2013, 2013, 1-4.	0.3	12
277	Survival and Recurrence for Patients Undergoing Surgery of Skull Base Intracranial Metastases. Journal of Neurological Surgery, Part B: Skull Base, 2013, 74, 228-235.	0.8	7
278	Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses. BioMed Research International, 2013, 2013, 1-8.	1.9	66
279	Threeâ€dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. Journal of Magnetic Resonance Imaging, 2013, 38, 1119-1128.	3.4	181
280	Patients undergoing surgery of intracranial metastases have different outcomes based on their primary pathology. Neurological Research, 2013, 35, 1059-1069.	1.3	12
281	Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors. Brain Tumor Research and Treatment, 2013, 1, 2.	1.0	15
282	Perspectives on key articles in neurosurgery. , 2012, 3, 58.		0
283	Real-Time Imaging with the O-Arm for Skull Base Applications: A Cadaveric Feasibility Study. Journal of Neurological Surgery, Part B: Skull Base, 2012, 73, 293-301.	0.8	9
284	Predictors of Visual Outcome Following Surgical Resection of Medial Sphenoid Wing Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2012, 73, 321-326.	0.8	22
285	Subependymoma: clinical features and surgical outcomes. Neurological Research, 2012, 34, 677-684.	1.3	64
286	Effectiveness of Repeat Glycerol Rhizotomy in Treating Recurrent Trigeminal Neuralgia. Neurosurgery, 2012, 70, 1125-1134.	1.1	21
287	Immunotherapy for Glioma. Neurosurgery Clinics of North America, 2012, 23, 357-370.	1.7	36
288	The role of STAT3 activation in modulating the immune microenvironment of GBM. Journal of Neuro-Oncology, 2012, 110, 359-368.	2.9	54

#	Article	IF	Citations
289	Potential Role for STAT3 Inhibitors in Glioblastoma. Neurosurgery Clinics of North America, 2012, 23, 379-389.	1.7	25
290	Stereotactic Radiosurgery of Cranial Arteriovenous Malformations and Dural Arteriovenous Fistulas. Neurosurgery Clinics of North America, 2012, 23, 133-146.	1.7	22
291	Clinical Trials with Immunotherapy for High-Grade Glioma. Neurosurgery Clinics of North America, 2012, 23, 459-470.	1.7	17
292	The predictive value of serum myeloperoxidase for vasospasm in patients with aneurysmal subarachnoid hemorrhage. Neurosurgical Review, 2012, 35, 413-419.	2.4	20
293	Heat shock proteinâ€“peptide complex in the treatment of glioblastoma. Expert Review of Vaccines, 2011, 10, 721-731.	4.4	23
294	Clinical Outcomes after Treatment of Germ Cell Tumors. Neurosurgery Clinics of North America, 2011, 22, 385-394.	1.7	12
295	Radiosurgery of Glomus Jugulare Tumors: A Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2011, 81, e497-e502.	0.8	107
296	Predictors of Inpatient Death and Complications among Postoperative Elderly Patients with Metastatic Brain Tumors. Annals of Surgical Oncology, 2011, 18, 521-528.	1.5	46
297	Surgical treatment of pediatric trigeminal neuralgia: case series and review of the literature. Child's Nervous System, 2011, 27, 2123-2129.	1.1	26
298	Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurgical Review, 2011, 34, 181-189.	2.4	29
299	Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series. Radiation Oncology, 2011, 6, 25.	2.7	8
300	Endoscopic transvestibular paramandibular exploration of the infratemporal fossa and parapharyngeal space: A minimally invasive approach to the middle cranial base. Laryngoscope, 2011, 121, 2075-2080.	2.0	32
301	The Radiosurgical Treatment of Arteriovenous Malformations: Obliteration, Morbidities, and Performance Status. International Journal of Radiation Oncology Biology Physics, 2011, 80, 354-361.	0.8	40
302	Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment. Clinical and Developmental Immunology, 2011, 2011, 1-20.	3.3	119
303	Delivery of stereotactic radiosurgery: a cross-platform comparison. Neurological Research, 2011, 33, 787-791.	1.3	5
304	Nelfinavir induces radiation sensitization in pituitary adenoma cells. Cancer Biology and Therapy, 2011, 12, 657-663.	3.4	25
305	Endoscopic Harvest and Transposition of Vascularized Pericranial Flap for Minimal Access Open and Endoscopic Skull Base Repair: Technical Notes and Case Illustration. Skull Base, 2011, 21, .	0.4	1
306	Stereotactic Radiosurgery in the Management of Brain Metastases: An Institutional Retrospective Analysis of Survival. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1486-1492.	0.8	45

#	Article	IF	Citations
307	Stereotactic Radiosurgery for Spine Tumors: Review of Current Literature. Stereotactic and Functional Neurosurgery, 2010, 88, 315-321.	1.5	22
308	Transpalpebral Orbitofrontal Craniotomy: A Minimally Invasive Approach to Anterior Cranial Vault Lesions. Skull Base, 2010, 20, 237-244.	0.4	28
309	Immunologic Consequences of Signal Transducers and Activators of Transcription 3 Activation in Human Squamous Cell Carcinoma. Cancer Research, 2010, 70, 6467-6476.	0.9	23
310	Biologic Principles of Immunotherapy for Malignant Gliomas. Neurosurgery Clinics of North America, 2010, 21, 1-16.	1.7	14
311	Preface. Neurosurgery Clinics of North America, 2010, 21, xv.	1.7	0
312	Immunotherapy Combined with Chemotherapy in the Treatment of Tumors. Neurosurgery Clinics of North America, 2010, 21, 187-194.	1.7	17
313	Mechanisms of Local Immunoresistance in Glioma. Neurosurgery Clinics of North America, 2010, 21, 17-29.	1.7	67
314	Radiosurgery for glomus jugulare: history and recent progress. Neurosurgical Focus, 2009, 27, E5.	2.3	35
315	A Virtual Frame System for Stereotactic Radiosurgery Planning. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1244-1249.	0.8	7
316	Radiosurgery for Glomus Jugulare Tumors. Technology in Cancer Research and Treatment, 2007, 6, 419-423.	1.9	40
317	CyberKnife radiosurgical rhizotomy for the treatment of atypical trigeminal nerve pain. Neurosurgical Focus, 2007, 23, E8.	2.3	13
318	Irradiation of glomus jugulare tumors: a historical perspective. Neurosurgical Focus, 2007, 23, E12.	2.3	27
319	CyberKnife Radiosurgery for Extremity Schwannomas: Technical Note and Case Report. Stereotactic and Functional Neurosurgery, 2006, 84, 60-63.	1.5	2
320	Stereotactic radiosurgery using CT cisternography and non-isocentric planning for the treatment of trigeminal neuralgia. Computer Aided Surgery, 2006, 11, 11-20.	1.8	28
321	Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-NaÃ¯ve Prostate Cancer. Clinical Cancer Research, 2006, 12, 3394-3401.	7.0	117
322	Stereotactic radiosurgery using CT cisternography and non-isocentric planning for the treatment of trigeminal neuralgia. Computer Aided Surgery, 2006, 11, 11-20.	1.8	2
323	CyberKnife radiosurgery for idiopathic trigeminal neuralgia. Neurosurgical Focus, 2005, 18, 1-7.	2.3	81
324	Î±vÎ²3 Integrin in central nervous system tumors. Human Pathology, 2005, 36, 665-669.	2.0	32

#	Article	IF	Citations
325	Efficacy and safety of stereotactic radiosurgery for glomus jugulare tumors. Neurosurgical Focus, 2004, 17, 68-72.	2.3	51
326	The Efficacy of Linear Accelerator Stereotactic Radiosurgery in Treating Glomus Jugulare Tumors. Technology in Cancer Research and Treatment, 2003, 2, 261-265.	1.9	34
327	Reversible Posterior Leukoencephalopathy Occurring during Resection of a Posterior Fossa Tumor: Case Report and Review of the Literature. Neurosurgery, 2001, 49, 1237-1240.	1.1	17
328	Diversity within the Neurosurgical Oncology Workforce in the United States: A Cross-Sectional Study with Proposed Strategies to Pave the Path Forward. Neuro-Oncology, 0, , .	1.2	0